----

----

| GLOSSARY                                                           | 3  |
|--------------------------------------------------------------------|----|
| TERMS OF REFERENCE                                                 | 4  |
| CAUTION REGARDING FORWARD-LOOKING STATEMENTS AND RISK FACTORS      | 4  |
| CORPORATE STRUCTURE                                                | 6  |
|      Intercorporate Relationships         | 7  |
| GENERAL DEVELOPMENT OF THE BUSINESS                                | 7  |
|      Three Year History                   | 7  |
| DESCRIPTION OF BUSINESS                                            | 9  |
|      Overview                             | 9  |
|      The CRH O'Regan System               | 11 |
|      Gastroenterology Anesthesia Services | 16 |
| RISK FACTORS                                                       | 19 |
|      Risks Related to Our Company         | 19 |
| DIVIDEND POLICY                                                    | 34 |
| DESCRIPTION OF CAPITAL STRUCTURE AND MARKET FOR SECURITIES         | 34 |
| PRIOR SALES                                                        | 35 |
| ESCROW SECURITIES                                                  | 36 |
| DIRECTORS AND OFFICERS                                             | 36 |
| CEASE TRADE ORDERS, BANKRUPTCIES, PENALTIES OR SANCTIONS           | 38 |
| CONFLICTS OF INTEREST                                              | 39 |
| AUDIT COMMITTEE INFORMATION                                        | 39 |
| Audit Committee Oversight                                          | 40 |
|      Reliance on Certain Exemptions       | 40 |
|      Pre-Approval Policies and Procedures | 40 |
|      External Auditor Service Fees        | 40 |
| INTEREST OF MANAGEMENT AND OTHERS IN MATERIAL TRANSACTIONS         | 40 |
| MATERIAL CONTRACTS                                                 | 41 |
| LEGAL PROCEEDINGS                                                  | 41 |
| NAMES AND INTEREST OF EXPERTS                                      | 41 |
| TRANSFER AGENTS AND REGISTRARS                                     | 42 |
| ADDITIONAL INFORMATION                                             | 42 |
| EXECUTIVE COMPENSATION                                             | 42 |
| ADDITIONAL FINANCIAL INFORMATION                                   | 42 |
| AUDIT COMMITTEE MANDATE                                            | 1  |

----

| Ambulatory Surgical Centers ("ASCs")                    | Healthcare facilities, also known as outpatient surgery centers or same-day surgery centers, where surgical procedures not requiring an overnight hospital stay are performed.                                                                                                                                                                                                                                                                                |
|---------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Anoscope                                                | An anoscope is an instrument used to view the anus and lowest portion of the rectum. An anoscope is a rigid tube (4 in or 10 cm long) that can be inserted with a lubricant into the anal canal. When the tube is inserted, a light source shone through the tube allows the examiner to see the wall of the anus and lower rectum. An anoscope is used to identify abnormalities in the anus and lower rectum, such as hemorrhoids, inflammation, or tumors. |
| Blind Technique                                         | Performing the hemorrhoid ligation without the use of the anoscope.                                                                                                                                                                                                                                                                                                                                                                                           |
| Colonoscopy                                             | Visual inspection of the interior of the colon with a flexible, lighted tube inserted through the rectum.                                                                                                                                                                                                                                                                                                                                                     |
| CRH O'Regan Ligator                                     | A disposable, minimally invasive hemorrhoid banding system.                                                                                                                                                                                                                                                                                                                                                                                                   |
| CRH O'Regan System®                                | This includes the CRH O'Regan Ligator as well as the CRH O'Regan Ligator with Anoscope.                                                                                                                                                                                                                                                                                                                                                                       |
| Certified Registered Nurse Anesthetists  ("CRNAs") | Registered nurses who have become anesthesia specialists by taking a graduate curriculum which focuses on the development of clinical judgment and critical thinking.                                                                                                                                                                                                                                                                                         |
| Dentate Line                                            | Where the anal canal meets the rectum there is a ring of folds called the dentate line. Among these folds are the anal crypts, small tube-like depressions opening into the anal canal. The dentate line delineates where nerve fibers end. Above this line, this area is relatively insensitive to pain. Below the dentate line, the anal canal and anus are extremely sensitive.                                                                            |
| Direct-to-physician program                             | CRH has leveraged the success of its Centers for Colorectal Health (which it operated across the United States between 2005 and 2010) to create its direct-to-physician program. The program consists of training, technology, practice support and marketing.                                                                                                                                                                                                |
| Embolism                                                | An obstruction in a blood vessel due to a blood clot or other foreign matter that gets trapped while travelling through the bloodstream.                                                                                                                                                                                                                                                                                                                      |
| Endoscopic Procedure                                    | Endoscopy is a minimally invasive diagnostic medical procedure. It is used to examine the interior surfaces of an organ or tissue. The endoscope can also be used for enabling biopsies and retrieving foreign objects.                                                                                                                                                                                                                                       |
| Gastroenterologists ("GIs")                             | Doctors specializing in diseases affecting gastrointestinal tract (i.e. organs from mouth to anus).                                                                                                                                                                                                                                                                                                                                                           |
| Hemorrhoids                                             | Normal blood vessels in the anal canal which when enlarged, can cause problems and can be considered abnormal or a disease.  Hemorrhoids can be either internal or external.  Internal fall into four categories depending on the degree of severity, grade one being the least severe and grade four being the most severe. Hemorrhoids are commonly referred to as Hemorrhoidal Disease.                                                          |
| Hemorrhoid banding                                      | A procedure where a small rubber band is placed around the base of the hemorrhoid inside the rectum, cutting off circulation, after which the hemorrhoid generally sloughs off within a few days.                                                                                                                                                                                                                                                             |

----

| Hemorrhoidectomy | Surgical removal of hemorrhoids.                                                                                                                                                                                                                                                                                                                                         |
|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Ligator          | An instrument used for hemorrhoid banding or for placing and fastening a ligature.                                                                                                                                                                                                                                                                                       |
| Propofol         | A prescription sedative-hypnotic drug (brand name Diprivan) that is administered intravenously. Propofol is commonly used in the induction of general anesthesia and can be used both for the induction and maintenance of general anesthesia. When administration of the drug is discontinued, it wears off rapidly, allowing the patient to awaken within a short time |
| Sepsis           | The presence of pus-forming bacteria or their toxins in the blood or tissues.                                                                                                                                                                                                                                                                                            |
| Sclerotherapy    | A treatment for varicose veins involving injecting a solution directly into the vein.                                                                                                                                                                                                                                                                                    |
| Thrombosis       | The formation or presence of a thrombus (a clot of coagulated blood attached at the site of its formation) in a blood vessel.                                                                                                                                                                                                                                            |

----

| · | Our need for additional financing and our estimates regarding our capital requirements, future revenues and profitability. |
|--------|----------------------------------------------------------------------------------------------------------------------------|

| · | Unfavourable economic conditions could have an adverse effect on our business. |
|--------|--------------------------------------------------------------------------------|

| · | Risks related to the Credit Facilities (as defined herein). |
|--------|-------------------------------------------------------------|

| · | Risks related to increased leverage resulting from incurring more debt. |
|--------|-------------------------------------------------------------------------|

| · | The policies of health insurance carriers may affect the amount of revenue the Company receives. |
|--------|--------------------------------------------------------------------------------------------------|

| · | Our ability to successfully market and sell our products and services. |
|--------|------------------------------------------------------------------------|

| · | We may be subject to competition and technological risk which may impact the price and amount of product we can sell and nature of services we can provide. |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | Changes that are unfavorable in the states where our operations are concentrated. |
|--------|-----------------------------------------------------------------------------------|

| · | Our ability to and the cost of compliance with extensive existing regulation and any changes or amendments thereto. |
|--------|---------------------------------------------------------------------------------------------------------------------|

| · | Changes within the medical industry and third-party reimbursement policies and our estimates of associated timing and costs with the same. |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------|

| · | Risks related to the Affordable Care Act (the "ACA") and the corresponding effect on our business. |
|--------|----------------------------------------------------------------------------------------------------|

| · | Changes in key United States federal or state laws, rules, and regulations. |
|--------|-----------------------------------------------------------------------------|

| · | Our ability to establish, maintain and defend intellectual property rights. |
|--------|-----------------------------------------------------------------------------|

| · | Risks related to United States antitrust regulations. |
|--------|-------------------------------------------------------|

| · | Risks related to record keeping and confidentiality by our affiliated physicians. |
|--------|-----------------------------------------------------------------------------------|

| · | Our ability to recruit and retain qualified physicians to provide our services. |
|--------|---------------------------------------------------------------------------------|

| · | Risks related to our affiliated physicians leaving our affiliated ASCs |
|--------|------------------------------------------------------------------------|

| · | Our ability to enforce non-competition and other restrictive covenants in our agreements. |
|--------|-------------------------------------------------------------------------------------------|

| · | ASCs or other customers may terminate or not renew their agreements. |
|--------|----------------------------------------------------------------------|

| · | Risks related to corporate practice of medicine and our ability to renew and maintain agreements with anesthesiologists and other contractors. |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------|

| · | Our ability and forecasts of expansion and the Company's management of anticipated growth. |
|--------|--------------------------------------------------------------------------------------------|

| · | Risks related to our dependence on complex information systems. |
|--------|-----------------------------------------------------------------|

| · | Our senior management has been key to our growth and we may be adversely affected if we are unable to retain, conflicts of interest develop or we lose any key member of our senior management. |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | Risks associated with manufacture of our products and our economic dependence on suppliers. |
|--------|---------------------------------------------------------------------------------------------|

| · | Changes in the industry and the economy may affect the Company's business. |
|--------|----------------------------------------------------------------------------|

| · | Risks related to the competitive nature of the medical industry. |
|--------|------------------------------------------------------------------|

| · | Evolving regulation of corporate governance and public disclosure may result in additional corporate expenses. |
|--------|----------------------------------------------------------------------------------------------------------------|

| · | Adverse events relating to our product or services could result risks relating to in product liability, medical malpractice, other legal claims, insurance, product recalls and other liabilities. |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | Various risks associated with legal, regulatory or investigative proceedings. |
|--------|-------------------------------------------------------------------------------|

----

| · | Risks associated with governmental investigations into marketing and other business practices. |
|--------|------------------------------------------------------------------------------------------------|

| · | Health and safety risks are intrinsic within our industry. |
|--------|------------------------------------------------------------|

| · | Our ability to successfully identify and complete future transactions and integrate our acquisitions. |
|--------|-------------------------------------------------------------------------------------------------------|

| · | Anti-takeover provisions create risks related to lost opportunities. |
|--------|----------------------------------------------------------------------|

| · | Risks related to influence of significant shareholders on our operations or common share price. |
|--------|-------------------------------------------------------------------------------------------------|

| · | We may not continue to attract GIs and other licensed providers to purchase and use the CRH O'Regan System or to provide our services. |
|--------|----------------------------------------------------------------------------------------------------------------------------------------|

| · | Risks associated with the trading of our common shares on a public marketplace. |
|--------|---------------------------------------------------------------------------------|

| · | Risks related to adverse movements in foreign currency exchange rates. |
|--------|------------------------------------------------------------------------|

| · | Risks related to maintaining our foreign private issuer status. |
|--------|-----------------------------------------------------------------|

| · | Risks related to writing-off intangible assets. |
|--------|-------------------------------------------------|

| · | Risks related to the reduction in the reimbursement of anesthesia procedure codes. |
|--------|------------------------------------------------------------------------------------|

| · | Changes in our effective income tax rates. |
|--------|--------------------------------------------|

| · | Risks related to our ability to manage third-party service providers. |
|--------|-----------------------------------------------------------------------|

| · | Risks related to the failure of our employees and third-party contractors appropriately recording or documenting services that they provide. |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------|

| · | Risks related to criminal or civil sanctions in connection with failure to comply with privacy regulations regarding the use and disclosure of patient information. |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Subsidiary                                    | Interest | Date of Incorporation | Jurisdiction of Incorporation |
|-----------------------------------------------|----------|-----------------------|-------------------------------|
| CRH Medical Corporation                       | 100%     | May 20, 2005          | Delaware, United States       |
| CRH Anesthesia Management LLC                 | 100%     | November 12, 2014     | Delaware, United States       |
| Gastroenterology Anesthesia Associates LLC(1) | -        | June 12, 2012         | Georgia, United States        |
| NC GAA, PC(1)                                 | -        | March 18, 2015        | North Carolina, United States |
| CRH Anesthesia of Gainesville LLC             | 100%     | October 31, 2014(2)   | Florida, United States        |
| CRH Anesthesia of Sarasota LLC                | 100%     | April 7, 2014(2)      | Florida, United States        |
| CRH Anesthesia of Cape Coral LLC              | 100%     | Jul 20, 2015          | Florida, United States        |
| CRH Anesthesia of Knoxville LLC               | 100%     | August 14, 2015       | Tennessee, United States      |

| (1) | The shares of Gastroenterology Anesthesia Associates, LLC and NC GAA P.C. are owned by individual medical practitioners. The operations and corporate structure of these subsidiaries are governed by certain agreements, including loans by CRH Medical Corporation (Delaware) to the individual medical practitioners.  These agreements, including the affirmative and negative covenants therein in favour of CRH, effectively provide CRH control of GAA and NC GAA. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2) | On February 23, 2015, IPS of Gainesville, LLC changed its name to CRH Anesthesia of Gainesville LLC.  On February 12, 2015, Coastal Anesthesia Providers, LLC changed its name to CRH Anesthesia of Sarasota LLC. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Subsidiary                                                    | Interest(1) | Date of Incorporation | Jurisdiction of Incorporation |
|---------------------------------------------------------------|-------------|-----------------------|-------------------------------|
| Macon Gastroenterology Anesthesia Associates LLC ("MGAA")     | 65%         | November 30, 2015     | Georgia, United States        |
| Knoxville Gastroenterology Anesthesia Associates LLC ("KGAA") | 51%         | July 29, 2015         | Tennessee, United States      |

| (1) | As a result of the operating agreements for the above entities, the Company effectively controls both MGAA and KGAA. |
|-----|----------------------------------------------------------------------------------------------------------------------|

----

----

| · | External – swollen vascular and soft tissue which is present below the "Dentate Line" which can often be seen and felt under the skin outside the anal canal. They often appear as a small bulge and are the same color as the skin. These can become irritated, inflamed or thrombosed, are generally treated by over the counter remedies or in some cases, a surgical procedure.  External hemorrhoids are often mistakenly "blamed" for patients' symptoms that are actually caused by their internal hemorrhoids, explaining why so many patients with "external" symptoms respond to treating their internal hemorrhoids.  |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | Internal – swollen and prolapsing vascular tissue which are inside of the anal opening, and form above the "Dentate Line".  When internal hemorrhoids become abnormal, they may protrude out through the anus while straining or during defecation. A reference to "hemorrhoids" in a clinical setting is generally a reference to internal hemorrhoids.  |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

----

----

|                                                   | CRH O'Regan System                            | McGiveny Ligator                                                           | Saeed "Short Shot"                                                 | Ultroid                                                                                            | Kilroid Not available in North America                             | HET                                                             | Endoscopic Banding                           |
|--------------------------------------------------------|-----------------------------------------------|----------------------------------------------------------------------------|--------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|--------------------------------------------------------------------|-----------------------------------------------------------------|----------------------------------------------|
| Assistance required                                    | No                                            | Often                                                                      | Often                                                              | Sometimes                                                                                          | Often                                                              | Often                                                           | Yes                                          |
| Length of procedure                                    | Approximately 1 minute                        | Approximately 5 - 15 minutes                                               | Approximately 5 - 10 minutes                                       | Approximately 10 - 20 minutes                                                                      | Approximately 5 - 10 minutes                                       | Approximately 5 - 10 minutes                                    | Approximately 10 - 30 minutes                |
| Patient comfort                                        | No Anoscope required, greater patient comfort | Anoscope and technique increase patient discomfort                         | Technique and multiple site banding increases patient discomfort   | Length of procedure and Probe used for procedure increase patient discomfort.                      | Technique increases patient discomfort                             | Most patients receive anesthesia because of risk of discomfort  | Requires bowel preparation and sedation      |
| Ease of Use by Physician                               | Easy to learn one handed technique            | 2 handed techniques required, instrumentation is more difficult to utilize | 2 handed technique required                                        | 2 handed technique required, length of procedure make instrumentation is more difficult to utilize | 2 handed technique required                                        | Requires specialized anoscope and grasping devices              | Requires endoscope and multiple assistance   |
| Cleaning                                               | Disposable                                    | Sterilization and maintenance required.                                    | Disposable, significantly more waste with suction tubing canisters | Disposable probe, hand piece not disposable and cannot be sterilized                               | Disposable, significantly more waste with suction tubing canisters | Disposable                                                      | Sterilization and maintenance required.      |
| Additional Equipment/Capital Investment  required | None                                          | Up front instrument purchase Cleaning and sterilizing expense              | Wall suction                                                       | Power generator                                                                                    | Wall suction                                                       | Current generator some instrumentation                          | Endoscopic facility and associated equipment |
| Training                                               | On-site physician training                    | None                                                                       | None                                                               | Non-physician onsite and video                                                                     | n/a                                                                | Non-physician onsite and video                                  | Training included in fellowship              |
| Other Support                                          | Marketing and operational                     | None                                                                       | None                                                               | Marketing and operational                                                                          | n/a                                                                | None                                                            | None                                         |
| Cost                                                   | $65 -75                                       | Initial cost + cost of cleaning and maintenance                            | $60 -65 (includes tubing and canisters)                            | $80                                                                                                | n/a                                                                | Initial investment plus a per treatment cost >$600/procedure | $250 + cost of endoscopy, ASC, etc.          |

----

----

| Patent Portfolio                                |
|-------------------------------------------------|
| Country                                         | Application or Patent Number | Title |
| US                                              | 7,029,438 | ANOSCOPE |
| CA                                              | 2,363,473 | ANOSCOPE |
| US                                              | 5,741,273 | ELASTIC BAND LIGATION DEVICE FOR THE TREATMENT OF HEMORRHOIDS |
| CA                                              | 2,240,850 | ELASTIC BAND LIGATION DEVICE FOR THE TREATMENT OF HEMORRHOIDS |
| Japan                                           | 4465179 | ELASTIC BAND LIGATION SYSTEM FOR TREATMENT OF HEMORRHOIDS |
| US                                              | US 9101360 | ELASTIC BAND LIGATION DEVICE WITH INTEGRATED OBTURATOR AND METHOD |
| US                                              | 13/972,168 - pending | ELASTIC BAND LIGATION DEVICE WITH LOCKING MECHANISM AND METHOD |
| US                                              | 13/972,202 - pending | ELASTIC BAND LIGATION DEVICE WITH ANTI-PINCH FEATURE AND METHOD |
| International – Patent Cooperation Treaty | PCT/US2013/066390 | ELASTIC BAND LIGATION DEVICE WITH INTEGRATED OBTURATOR AND METHOD |
| International – Patent Cooperation Treaty | PCT/US2013/066397 | ELASTIC BAND LIGATION DEVICE WITH LOCKING MECHANISM AND METHOD |
| International – Patent Cooperation Treaty | PCT/US2013/066407 | ELASTIC BAND LIGATION DEVICE WITH ANTI-PINCH FEATURE AND METHOD |
| United States - (US)                            | 14/807,304 | ELASTIC BAND LIGATION DEVICE WITH INTEGRATED OBTURATOR AND METHOD FOR TREATMENT OF HEMORRHOIDS |
| China P.R. - (CN)                               | PCT/US2013/066390 | ELASTIC BAND LIGATION DEVICE WITH INTEGRATED OBTURATOR AND METHOD FOR TREATMENT OF HEMORRHOIDS |
| European Patent Convention - (EP)               | 13891750.5 | ELASTIC BAND LIGATION DEVICE WITH INTEGRATED OBTURATOR AND METHOD FOR TREATMENT OF HEMORRHOIDS |
| China P.R. - (CN)                               | PCT/US2013/066397 | ELASTIC BAND LIGATION DEVICE WITH LOCKING MECHANISM AND METHOD FOR TREATMENT OF HEMORRHOIDS |
| European Patent Convention - (EP)               | PCT/US2013/066397 | ELASTIC BAND LIGATION DEVICE WITH LOCKING MECHANISM AND METHOD FOR TREATMENT OF HEMORRHOIDS |
| China P.R. - (CN)                               | PCT/US2013/066407 | ELASTIC BAND LIGATION DEVICE WITH ANTI-PINCH FEATURE AND METHOD FOR TREATMENT OF HEMORRHOIDS |
| European Patent Convention - (EP)               | 13892001.2 | ELASTIC BAND LIGATION DEVICE WITH ANTI-PINCH FEATURE AND METHOD FOR TREATMENT OF HEMORRHOIDS |
| India - (IN)                                    | PCT/US2013/066390 | ELASTIC BAND LIGATION DEVICE WITH INTEGRATED OBTURATOR AND METHOD FOR TREATMENT OF HEMORRHOIDS |
| Japan - (JP)                                    | PCT/US2013/066390 | ELASTIC BAND LIGATION DEVICE WITH INTEGRATED OBTURATOR AND METHOD FOR TREATMENT OF HEMORRHOIDS |
| India - (IN)                                    | PCT/US2013/066397 | ELASTIC BAND LIGATION DEVICE WITH LOCKING MECHANISM AND METHOD FOR TREATMENT OF HEMORRHOIDS |
| Japan - (JP)                                    | PCT/US2013/066397 | ELASTIC BAND LIGATION DEVICE WITH LOCKING MECHANISM AND METHOD FOR TREATMENT OF HEMORRHOIDS |
| India - (IN)                                    | PCT/US2013/066407 | ELASTIC BAND LIGATION DEVICE WITH ANTI-PINCH FEATURE AND METHOD FOR TREATMENT OF HEMORRHOIDS |
| Japan - (JP)                                    | PCT/US2013/066407 | ELASTIC BAND LIGATION DEVICE WITH ANTI-PINCH FEATURE AND METHOD FOR TREATMENT OF HEMORRHOIDS |

----

----

----

----

| · | we experience more competition from other companies or in more markets than anticipated; |
|--------|------------------------------------------------------------------------------------------|

| · | we experience delays or unexpected increases in costs in connection with maintaining regulatory approvals for our product or services in the various markets where we sell our product and provide our services; |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | we experience unexpected or increased costs relating to preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, or other lawsuits, brought by either us or our competition; |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | we elect to raise additional capital in order to service or repay all or a portion of our outstanding debt; |
|--------|-------------------------------------------------------------------------------------------------------------|

| · | we elect to develop, acquire or license new technologies, products or businesses; or |
|--------|--------------------------------------------------------------------------------------|

| · | we are presented with suitable opportunities and elect to accelerate the pace of our continued growth strategy. |
|--------|-----------------------------------------------------------------------------------------------------------------|

----

----

| · | safety, efficacy, convenience and cost-effectiveness of our products and services; |
|--------|------------------------------------------------------------------------------------|

| · | scope of approved uses and marketing approval; |
|--------|------------------------------------------------|

| · | difficulty in, or excessive costs to, manufacturing; |
|--------|------------------------------------------------------|

| · | infringement or alleged infringement of the patents or intellectual property rights of others; |
|--------|------------------------------------------------------------------------------------------------|

| · | maintenance of business arrangements with healthcare providers; |
|--------|-----------------------------------------------------------------|

| · | availability of alternative products or services from our competitors; and |
|--------|----------------------------------------------------------------------------|

| · | acceptance of the price of our products and services. |
|--------|-------------------------------------------------------|

| · | are more effective; |
|--------|---------------------|

| · | have fewer or less severe adverse side effects; |
|--------|-------------------------------------------------|

| · | have better patient compliance; |
|--------|---------------------------------|

| · | receive better reimbursement terms; |
|--------|-------------------------------------|

| · | are accepted by more physicians; |
|--------|----------------------------------|

| · | have better distribution channels; |
|--------|------------------------------------|

| · | are easier to administer; or |
|--------|------------------------------|

| · | are less expensive. |
|--------|---------------------|

----

| · | payment for services; |
|--------|-----------------------|

| · | corporate practice of medicine; |
|--------|---------------------------------|

| · | conduct of operations, including fraud and abuse, anti-kickback, physician self-referral, and false claims prohibitions; |
|--------|--------------------------------------------------------------------------------------------------------------------------|

| · | protection of patient information; and |
|--------|----------------------------------------|

| · | medical waste disposal and environmental protection. |
|--------|------------------------------------------------------|

----

----

| · | obtain patents or rights to patents and maintain their validity; |
|--------|------------------------------------------------------------------|

| · | protect our trade secrets; and |
|--------|--------------------------------|

| · | effectively enforce our proprietary rights or patents against infringers. |
|--------|---------------------------------------------------------------------------|

----

----

----

----

----

----

----

| · | exposure to unknown liabilities of acquired companies and the unknown issues with any associated technologies or research. Such liabilities may include liabilities for failure to comply with applicable laws, or liabilities relating to medical malpractice claims. Generally we obtain indemnification agreements from the sellers of businesses acquired with respect to pre-closing acts, omissions and other similar risks. It is possible that we may seek to enforce indemnification provisions in the future against sellers who may no longer have the financial wherewithal to satisfy their obligations to us. Accordingly, we may incur material liabilities for past activities of acquired businesses; |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | certain acquired businesses may derive a greater portion of their revenue from government health programs than what we recognize on a consolidated basis or that have business models with lower operating margins than ours, which could affect our overall payor mix or operating results in future periods; |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | higher than anticipated acquisition costs and expenses; |
|--------|---------------------------------------------------------|

| · | exposure to other companies' shares that shareholders could receive as consideration for our shares in a corporate transaction; |
|--------|---------------------------------------------------------------------------------------------------------------------------------|

| · | the difficulty and expense of integrating operations, systems, and personnel of acquired companies; |
|--------|-----------------------------------------------------------------------------------------------------|

| · | disruption of our ongoing business; |
|--------|-------------------------------------|

| · | uncertainty an acquired business will continue to maintain its pre-acquisition revenue and growth rates or be financially successful; |
|--------|---------------------------------------------------------------------------------------------------------------------------------------|

| · | inability to retain key customers, distributors, vendors and other business partners of the acquired company; |
|--------|---------------------------------------------------------------------------------------------------------------|

| · | diversion of management's time and attention; |
|--------|-----------------------------------------------|

| · | the realization of financial and operating risks not fully anticipated; and |
|--------|-----------------------------------------------------------------------------|

| · | potential challenges under antitrust laws either before or after an acquisition is consummated, which could involve substantial legal costs and result in us having to abandon the transaction or make a divestiture. |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

----

----

| 2015      | Max      | Min      | End      | Total Volume |
|-----------|----------|----------|----------|--------------|
| January   | CAD$2.50 | CAD$1.90 | CAD$2.41 | 10,921,900   |
| February  | CAD$4.15 | CAD$2.35 | CAD$3.69 | 11,337,200   |
| March     | CAD$3.90 | CAD$3.21 | CAD$3.45 | 11,468,100   |
| April     | CAD$4.37 | CAD$3.13 | CAD$3.46 | 9,817,200    |
| May       | CAD$4.01 | CAD$3.30 | CAD$3.70 | 5,724,900    |
| June      | CAD$4.90 | CAD$3.67 | CAD$4.74 | 8,043,300    |
| July      | CAD$5.45 | CAD$4.35 | CAD$5.05 | 13,171,700   |
| August    | CAD$5.50 | CAD$2.85 | CAD$4.63 | 11,372,200   |
| September | CAD$5.35 | CAD$3.89 | CAD$4.27 | 12,726,500   |
| October   | CAD$4.40 | CAD$3.62 | CAD$3.73 | 8,903,300    |
| November  | CAD$4.04 | CAD$2.94 | CAD$3.85 | 7,500,300    |
| December  | CAD$4.47 | CAD$2.98 | CAD$4.10 | 7,346,200    |
| 2015      | Max         | Min         | End                | Total Volume                                                                    |
|-----------|-------------|-------------|--------------------|---------------------------------------------------------------------------------|
| January   |  $1.96 |  $1.63 |  $  1.91 |          1,330,600                 |
| February  |  $3.33 |  $1.91 |  $  2.91 |          1,272,700                 |
| March     |  $3.13 |  $2.58 |  $  2.74 |             354,300 |
| April     |  $3.48 |  $2.70 |  $  2.98 |             252,200 |
| May       |  $3.30 |  $2.85 |  $  2.98 |             371,700 |
| June      |  $3.90 |  $2.98 |  $  3.80 |             474,700 |
| July      |  $4.19 |  $3.52 |  $  3.86 |             423,200 |
| August    |  $4.18 |  $2.25 |  $  3.56 |             277,200 |
| September |  $4.25 |  $2.95 |  $  3.20 |             373,700 |
| October   |  $3.38 |  $2.80 |  $  2.88 |             597,600 |
| November  |  $3.05 |  $2.19 |  $  2.88 |             532,000 |
| December  |  $3.23 |  $2.18 |  $  2.95 |             374,700 |

----

| Exercise Date     | Number of Shares | Exercise Price |
|-------------------|------------------|----------------|
| February 18, 2015 | 12,500           | CAD$0.275      |
| March 3, 2015     | 50,000           | CAD$1.45       |
| March 3, 2015     | 18,750           | CAD$0.56       |
| March 3, 2015     | 12,500           | CAD$0.275      |
| March 3, 2015     | 25,000           | CAD$1.90       |
| March 6, 2015     | 10,000           | CAD$1.00       |
| May 6, 2015       | 100,000          | CAD$1.45       |
| May 6, 2016       | 25,000           | CAD$1.38       |
| May 6, 2015       | 101,563          | CAD$0.56       |
| May 6, 2015       | 14,063           | CAD$0.275      |
| May 6, 2015       | 7,813            | CAD$0.60       |
| May 7, 2015       | 100,000          | CAD$1.45       |
| July 31, 2015     | 15,000           | CAD$1.20       |
| August 4, 2015    | 10,000           | CAD$1.20       |
| August 28, 2015   | 15,000           | CAD$1.20       |
| October 5, 2015   | 10,000           | CAD$1.20       |
| November 18, 2015 | 15,000           | CAD$0.56       |
| November 30, 2015 | 75,000           | CAD$1.38       |
| December 3, 2015  | 25,000           | CAD$1.20       |
| December 3, 2015  | 80,000           | CAD$0.56       |
| December 4, 2015  | 25,000           | CAD$1.38       |
| December 18, 2015 | 11,000           | CAD$0.56       |
| Total             | 758,189          |           |
| Vesting Date  | Number of Shares |
|---------------|------------------|
| July 24, 2015 | 1,000,000        |
| Total         | 1,000,000        |
| Grant Date         | Number of Share Units |
|--------------------|-----------------------|
| February 20, 2015  | 2,276,000             |
| April 30, 2015     | 115,000               |
| September 17, 2015 | 25,000                |
| December 10, 2015  | 93,000                |
| Total              | 2,509,000             |
| Issuance Date      | Number of Shares | Issue Price | Reason for Issuance     |
|--------------------|------------------|-------------|-------------------------|
| March 25, 2015     | 8,050,000        | CAD$3.40    | Bought Deal Offering    |
| September 10, 2015 | 375,612          | CAD$5.01    | KGAA Acquisition        |
| September 17, 2015 | 140,795          | CAD$3.40    | Broker Warrant Exercise |
| Total              | 8,566,407        |        |                    |

----

----

----

| Name              | Number of Common Shares | Percentage of Outstanding Common Shares | Number of Common Shares held under Options and Warrants |
|-------------------|-------------------------|-----------------------------------------|---------------------------------------------------------|
| Anthony F. Holler | 1,525,000               | 2.14%                                   | 191,000                                                 |
| Todd R. Patrick   | 926,689                 | 1.30%                                   | 67,561                                                  |
| Ian A. Webb       | 53,500                  | 0.08%                                   | 191,000                                                 |
| Edward Wright     | 10,000                  | 0.01%                                   | 1,500,000                                               |
| Dave Johnson      | 285,900                 | 0.40%                                   | 191,000                                                 |
| Bergein Overholt  | 75,000                  | 0. 11%                                  | 91,000                                                  |
| Richard Bear      | 290,000                 | 0.41%                                   | 1,050,000                                               |
| TOTAL             | 3,166,089               |                                    | 3,281,561                                               |

|  | (a) | is, or has been within the 10 years prior to the date of this Annual Information Form, a director, chief executive officer or chief financial officer of any company that, while that person was acting in that capacity, (i) was the subject of a cease trade or similar order or an order that denied the company access to any exemptions under securities legislation for a period of more than 30 consecutive days, (ii) was subject to a cease trade order or similar order or an order that denied the relevant company an exemption under securities legislation that was issued after the director or executive officer ceased to be a director, chief executive officer or chief financial officer and which resulted from an event that occurred while that person was acting in the capacity as director, chief executive officer or chief financial officer. |
|--|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (b) | nor, to the knowledge of the Company, a shareholder holding a sufficient number of securities of the Company to affect materially the control of the Company is, or has been, within the last ten years, a director of executive officer of a company that, while the that person was acting in that capacity, or within a year of ceasing to act in that capacity, declared bankrupt or made a proposal under any legislation relating to bankruptcy or insolvency or has been subject to or instituted any proceedings, arrangement or compromise with creditors or had a receiver, receiver manager or trustee appointed to hold the assets of that company. |
|--|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (c) | nor, to the knowledge of the Company,  a shareholder holding a sufficient number of securities of the Company to affect materially the control of the Company has, within the ten years prior to the date of this Annual Information Form become bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency or been subject to or instituted any proceedings, arrangement, or compromise with creditors or had a receiver, receiver manager or trustee appointed to hold his or her assets. |
|--|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (d) | nor, to the knowledge of the Company, a shareholder holding a sufficient number of securities of the Company to affect materially the control of the Company, has (i) been subject to any penalties or sanctions imposed by a court relating to securities legislation or by a securities regulatory authority or have entered into a settlement agreement with a securities regulatory authority; or (ii) been subject to any other penalties or sanctions imposed by a court or regulatory body that would likely be considered important to a reasonable investor in making an investment decision. |
|--|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 1. | The Audit Committee's Charter  |
|----|-------------------------------------|

| 2. | Composition of the Audit Committee  |
|----|------------------------------------------|

| Name               | Independent/non-independent | Financially literate or not financially literate | Relevant Education and Experience                                                                                   |
|--------------------|-----------------------------|--------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|
| Dr. Anthony Holler | Independent (1)             | Financially literate(2)                          | Previously CEO and Director of ID Biomedical                                                                        |
| Todd Patrick       | Independent (1)             | Financially literate(2)                          | Previously President and Director of ID Biomedical, Masters of Business Administration – emphasis in finance. |
| Ian Webb           | Independent (1)             | Financially literate(2)                          | Retired Solicitor practicing corporate law and previously Director of ID Biomedical                                 |

| (1) | A member of an audit committee is independent if the member has no direct or indirect material relationship with the Company, which could, in the view of the Board of Directors, reasonably interfere with the exercise of a member's independent judgment. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2) | An individual is financially literate if he has the ability to read and understand a set of financial statements that present a breadth of complexity of accounting issues that are generally comparable to the breadth and complexity of the issues that can reasonably be expected to be raised by the Company's financial statements. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|               | Year ended December 31, 2014 | Year ended December 31, 2015 |
|--------------------|------------------------------|------------------------------|
| Audit Fees         | CAD$175,000                  | CAD$372,000                  |
| Audit-Related Fees | CAD$225,956                  | CAD$nil                      |
| Tax Fees           | CAD$85,815                   | CAD$79,482                   |
| All Other Fees     | CAD$nil                      | CAD$nil                      |
| Total              | CAD$486,771                  | CAD$451,482                  |

----

| Financial Covenant          | Required Ratio |
|-----------------------------|----------------|
| Senior debt to EBITDA ratio | 2.25:1.00      |
| Total funded debt ratio     | 3.00:1.00      |
| Fixed charge coverage ratio | 1.30:1.00      |

----

----

|  | · | reviewing the integrity of the consolidated financial statements of the Corporation; |
|--|--------|--------------------------------------------------------------------------------------|

|  | · | appointing (subject to shareholder ratification if required), determining funding for, and overseeing the external auditor and reviewing the external auditor's qualifications and independence; |
|--|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | reviewing the performance of the Corporation's external auditors; |
|--|--------|-------------------------------------------------------------------|

|  | · | reviewing the timely compliance by the Corporation with all legal and regulatory requirements for audit and related financial functions of the Corporation; |
|--|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | reviewing, and if applicable, approving, financial information contained in public filings of the Corporation prior to filing; |
|--|--------|--------------------------------------------------------------------------------------------------------------------------------|

|  | · | reviewing earnings announcements of the Corporation prior to release to the public; |
|--|--------|-------------------------------------------------------------------------------------|

|  | · | reviewing the Corporation's systems of and compliance with internal financial controls; |
|--|--------|-----------------------------------------------------------------------------------------|

|  | · | reviewing the Corporation's auditing, accounting and financial reporting processes; |
|--|--------|-------------------------------------------------------------------------------------|

|  | · | dealing with all complaints regarding accounting, internal accounting controls and auditing matters; and |
|--|--------|----------------------------------------------------------------------------------------------------------|

|  | · | dealing with any issues that result from the reviews set forth above. |
|--|--------|-----------------------------------------------------------------------|

| 1. | The Audit Committee will have a minimum of three members. |
|----|-----------------------------------------------------------|

| 2. | Each member of the Audit Committee must be independent. "Independent" shall have the meaning, given to it in National Instrument 52-110 - Audit Committees, as may be amended from time to time, and within the meaning of Section 301 of the Sarbanes-Oxley Act of 2002 ("Sarbanes-Oxley"), the rules promulgated thereunder by the Securities and Exchange Commission (the "SEC") and the rules of the NYSE MKT, and, as such, shall be free from any relationship that may interfere with the exercise of his or her independent judgment as a member of the Audit Committee. |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3. | At the time of his or her appointment to the Audit Committee, each member of the Audit Committee shall be financially literate.  "Financial literacy" shall be determined by the Board in the exercise of its business judgment, and shall include the ability to read and understand a set of financial statements that present a breadth and level of complexity of accounting issues that are generally comparable to the breadth and complexity of the issues that can reasonably be expected to be raised by the Corporation's financial statements. |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 4. | At least one member of the Audit Committee shall be an "audit committee financial expert" within the meaning of Section 407 of Sarbanes-Oxley and the rules promulgated thereunder by the SEC. |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5. | Appointments and replacements to the Audit Committee will be made by the Board and will be reviewed on an annual basis.  The Board will provide for continuity of membership, while at the same time allowing fresh perspectives to be added.  Each member of the Audit Committee will automatically cease to be a member if he or she ceases to be an independent director. |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6. | The Chair of the Audit Committee will be appointed by a vote of the Board on an annual basis. |
|----|-----------------------------------------------------------------------------------------------|

| 1. | The Audit Committee may meet as many times per year as necessary to carry out its responsibilities, but must meet at least once every quarter. No business may be transacted at a meeting unless a quorum of the Audit Committee is present. Two members of the Audit Committee shall constitute a quorum. |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2. | The Audit Committee shall maintain minutes or other forms of records of the meetings and activities of the Audit Committee in sufficient detail to convey the substance of all discussions held, and shall report to the Board, within a reasonable time period, the proceedings of the Audit Committee and any recommendations made by the Audit Committee. |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3. | Meetings of the Audit Committee will be held at the request of any member of the Audit Committee or at the request of the Corporation's external auditors. The Corporation's external auditor is entitled to receive notice of every meeting of the Audit Committee and to attend and be heard at every meeting, at the expense of the Corporation and, if so requested by a member of the Audit Committee, shall attend every meeting of the committee held during the term of office of the auditor. |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4. | The Audit Committee may invite to a meeting any officers or employees of the Corporation, legal counsel, advisors and other persons whose attendance it considers necessary or desirable in order to carry out its responsibilities. Provision will be made to meet privately with external auditors. |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1. | The Audit Committee will review the Corporation's financial statements, management discussion and analysis ("MD&A") and the related press releases before such documents are presented to the Board or disclosed publicly, as the case may be. |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2. | The Audit Committee will review the interim financial statements of the Corporation, the related MD&A, and the press release thereon. If advisable, the Audit Committee shall approve, on behalf of the Board, the interim financial statements and related MD&A for public disclosure. |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3. | The Audit Committee will review the annual audited financial statements of the Corporation, the auditor's report thereon, the related MD&A, and the press release thereon. If advisable, the Audit Committee shall approve and recommend for Board approval the annual financial statements and related MD&A. |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4. | The Audit Committee will review other financial information and financial documents that require the approval of the Board.  These will include statements in prospectuses and other offering memoranda and statements required by regulatory authorities. After completing its review, if advisable, the Audit Committee shall approve and recommend for Board approval such financial information. |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5. | The Audit Committee will issue any necessary reports required of the Audit Committee to be included in the Corporation's annual proxy materials. |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------|

| 6. | The Audit Committee will review and discuss with management and the external auditor any major issue as to the adequacy and effectiveness of internal controls over the accounting and financial reporting systems of the Corporation, either directly, or through the external auditors or other advisors and obtain and review a report from the external auditor, at least annually, regarding the same; and the Audit Committee will review and discuss with management and the external auditor any special steps adopted in light of material internal control deficiencies and the adequacy of disclosures about changes in internal controls over financial reporting. |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 7. | The Audit Committee will review, with the external auditors, the results of the external audit and any changes in accounting practices or policies, or in the financial statements as a result thereof.  In addition, the Audit Committee will review any accruals, provisions, or estimates that have a significant effect upon the financial statements, as well as other sensitive matters such as disclosure of related party transactions. |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8. | The Audit Committee will discuss with management and the external auditor any correspondence with regulators or governmental agencies and any published reports that raise material issues regarding the Corporation's financial statements or accounting policies. |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1. | The Audit Committee is responsible for overseeing the work of the external auditor and will communicate directly with the external auditors as required. The external auditor of the Corporation must report directly to the Audit Committee. |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2. | The Audit Committee shall review and, if advisable, select and recommend for Board approval the external auditors to be nominated and the compensation of such external auditor. The Audit Committee shall have ultimate authority to approve all audit engagement terms and fees. |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3. | The Audit Committee will evaluate the qualifications, performance and independence of the external auditor and the senior audit partners having primary responsibility for the audit, including considering whether the auditor's quality controls are adequate. |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4. | The Audit Committee will receive from the external auditor a formal written statement delineating all relationships between the external auditor and the Corporation and will actively engage in a dialogue with the external auditor with respect to any disclosed relationships or services that may impact the objectivity and independence of the external auditors. |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5. | The Audit Committee must pre-approve all non-audit services to be provided to the Corporation by the external auditor. Notwithstanding the foregoing, the Audit Committee: (a) may delegate to one or more members the authority to pre-approve any non-audit service to be provided by the external auditor, to the extent permitted by applicable law, provided that any pre-approvals granted pursuant to such delegation will be reported to the full Audit Committee at its next scheduled meeting; and (b) establish policies and procedures, from time to time, pre-approving certain non-audit services to be provided by the external auditor,  provided (i) such pre-approval policies and procedures are detailed as to the particular service, (ii) the Audit Committee is informed of each non-audit service, and (iii) the procedures do not include delegation of the Audit Committee's responsibilities to management. |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6. | The Audit Committee will review and approve the Corporation's hiring of partners, employees, former partners and former employees of the present and former external auditor of the Corporation. |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7. | The Audit Committee has the authority, to the extent it deems necessary or appropriate, to retain independent legal, accounting or other advisors.  The Corporation will provide appropriate funding, as determined by the Audit Committee, for payment of compensation to the external auditor for the purpose of rendering or issuing an audit report or performing other audit, review or attest services and to any advisors employed by the Audit Committee. |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 1. | The Audit Committee will establish procedures for the receipt, retention and treatment of complaints received by the Corporation regarding accounting, internal accounting controls or auditing matters and for the confidential, anonymous submission by employees of the Corporation of concerns regarding questionable accounting or auditing matters. |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2. | The Audit Committee will review the policies and practices of the Corporation regarding the regular examination of officers' expenses and perquisites, including the use of the assets of the Corporation. |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3. | The Corporation must provide appropriate funding, as determined by the Audit Committee, for payment of ordinary administrative expenses of the Audit Committee that are necessary or appropriate in carrying out its duties. |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4. | The Audit Committee will review and, if advisable, approve all related party transactions. |
|----|--------------------------------------------------------------------------------------------|

| 5. | The Audit Committee will review and reassess the adequacy of this mandate as it deems appropriate but no less than annually. |
|----|------------------------------------------------------------------------------------------------------------------------------|

----